Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines

Background: Exendin-4 is a peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor, currently in clinical trials as a potential disease-modifying therapy for Parkinson’s disease. In light of this, it is important to understand potential modes of action of exendin-4 in the brain. Exendin-4 is...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Parkinsons Dis
Päätekijät: Ventorp, Filip, Bay-Richter, Cecilie, Nagendra, Analise Sauro, Janelidze, Shorena, Matsson, Viktor Sjödahl, Lipton, Jack, Nordström, Ulrika, Westrin, Åsa, Brundin, Patrik, Brundin, Lena
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: IOS Press 2017
Aiheet:
Research Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5438473/
https://ncbi.nlm.nih.gov/pubmed/28387682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-171068
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia